TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01769456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCC
Description: Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Study: NCT03640416

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit® Charge HR smart watch
Description: The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
Study: NCT04401215

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)
Description: This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
Study: NCT03757026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: 20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slip Training
Description: 20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harnessed gaming
Description: 20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
Study: NCT04993144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous theta burst stimulation
Description: stimulatory protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation
Description: stimulatory protocol
Study: NCT01041872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-lipuro B. Braun plain
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study: NCT03484546

Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma cyst excision
Description: laparoscopic resection of ovarian endometrioma

Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma cyst excision
Description: laparoscopic resection of ovarian endometrioma

Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma cyst excision
Description: laparoscopic resection of ovarian endometrioma
Study: NCT01041872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-lipuro B. Braun plus lidocaine
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Fresenius plain
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Fresenius plus lidocaine
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study: NCT03930706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longer administration of estradiol (Progynova®)
Description: All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longer administration of estradiol (Progynova®)
Description: All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
Study: NCT03673020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Description: Neoantigen Vaccine
Study: NCT04356963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Session (VR Blu)
Description: 20-30 minute session of virtual reality immersive content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based Session (Tablet Blu)
Description: 20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality Head Mounted Display without Content (VR Blank)
Description: 20-30 minutes session using head mounted display to reduce light and sound.
Study: NCT02894177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tcPCO2 measurement
Description: tcPCO2 continuous monitoring during spontaneous breathing trials
Study: NCT01602250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid®
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid®
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
Study: NCT03779711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous (self) mononuclear cells derived from umbilical cord blood
Description: The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stage II Surgical repair
Description: This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stage II Surgical repair
Description: This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
Study: NCT00649896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Estradiol Transdermal System 0.025 mg/day
Study: NCT00676832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solid capsule dosage form administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED
Description: The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
Study: NCT00649896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climara® Transdermal System 0.025 mg/day
Study: NCT00148941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 1
Description: SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 2
Description: SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 3
Description: SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix
Description: Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPOL
Description: IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
Study: NCT03050320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.

Intervention type: OTHER
Group type: OTHER
Intervention: No Exercise
Description: A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
Study: NCT02668913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic analysis
Description: Molecular profiling
Study: NCT02971553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Resuscitator with PEEP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upright Resuscitator
Study: NCT00995657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Inhaled Fluticasone Propionate 50mcg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Inhaled Fluticasone Propionate 250mcg bid
Study: NCT01596036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early appointment (within 10 days)
Description: Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine referral (at 5 weeks)
Description: Standard Referral to Cardiac Rehabilitation
Study: NCT01651663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol (Umifenovir)
Description: Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol (Umifenovir)
Description: Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
Study: NCT03997656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyDiPP (Malaysia Diabetes Prevention Program)
Description: The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
Study: NCT01757288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB-PACLITAXEL
Description: nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
Study: NCT00085449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04286516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Paired pulse transcranial magnetic stimulation
Study: NCT04720092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Granules for oral suspension, 10 mg, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Granules for oral suspension, 10 mg, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablet, 10 mg, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablet, 10 mg, oral, single dose
Study: NCT02828020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: 50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: 50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study: NCT02727491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
Study: NCT02769169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis® (Raibizumab) double-dose
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis® (Raibizumab) regular-dose
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
Study: NCT01183065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate With Vitamin B12 and Folic Acid
Description: Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
Study: NCT01870648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study: NCT02394717

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Eating and Physical Activity
Description: Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
Study: NCT00330681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-186
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT05374629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use different methods of teaching
Description: Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
Study: NCT00621140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01656668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC1036
Study: NCT03870412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.